Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

Thumbnail for Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

MM - 1202

Real-World Survival and Safety of Isatuximab-Based vs Daratumumab-Based VRd Exposure in Multiple Myeloma

Xiaoyi Zhang

Poster Presenter: Xiaoyi Zhang

Thumbnail for Real-World Incidence of Severe Ventricular Arrhythmias in Patients with Acute Myeloid Leukemia Treated with Quizartinib: Interim Results From a Postmarketing Study

AML - 1204

Real-World Incidence of Severe Ventricular Arrhythmias in Patients with Acute Myeloid Leukemia Treated with Quizartinib: Interim Results From a Postmarketing Study

Akash Nahar

Poster Presenter: Akash Nahar

Thumbnail for Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma: From Surrogate Endpoint Validation to the Unanswered Question of Maintenance-Free Remission

MM - 1205

Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma: From Surrogate Endpoint Validation to the Unanswered Question of Maintenance-Free Remission

Sukhmani Sidhu

Poster Presenter: Sukhmani Sidhu

Thumbnail for Discovery and Characterization of DMR-001, an Fc-Null, Half-Life-Optimized Monoclonal Antibody Selectively Targeting Mutant Calreticulin

MPN - 1206

Discovery and Characterization of DMR-001, an Fc-Null, Half-Life-Optimized Monoclonal Antibody Selectively Targeting Mutant Calreticulin

Mark Benton

Poster Presenter: Mark Benton

Thumbnail for Efficacy and Safety of Venetoclax Plus Azacitidine in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

AML - 1207

Efficacy and Safety of Venetoclax Plus Azacitidine in Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Fatima Nadeem

Poster Presenter: Fatima Nadeem

Thumbnail for Sex-Based Differences in Hematologic Malignancy Mortality Across Therapeutic Eras in the United States: A CDC WONDER Analysis (1999-2020)

AML - 1208

Sex-Based Differences in Hematologic Malignancy Mortality Across Therapeutic Eras in the United States: A CDC WONDER Analysis (1999-2020)

Nihar Prafullchandra Vavaliya

Poster Presenter: Nihar Prafullchandra Vavaliya

Thumbnail for Whole Genome Sequencing of Patients with Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard Of Care Methods

MDS - 1210

Whole Genome Sequencing of Patients with Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard Of Care Methods

Alex Bataller

Poster Presenter: Alex Bataller

Thumbnail for Competing Risks Analysis of Age-Related and Temporal Trends in Acute Myeloid Leukemia Mortality: A SEER-Based Study (2000-2023)

AML - 1211

Competing Risks Analysis of Age-Related and Temporal Trends in Acute Myeloid Leukemia Mortality: A SEER-Based Study (2000-2023)

Ashesh Kumar

Poster Presenter: Ashesh Kumar

Thumbnail for Post-Induction Consolidation With Blinatumomab vs Chemotherapy in First-Relapse B-Cell Acute Lymphoblastic Leukemia: Evidence From Randomized Controlled Trials

ALL - 1212

Post-Induction Consolidation With Blinatumomab vs Chemotherapy in First-Relapse B-Cell Acute Lymphoblastic Leukemia: Evidence From Randomized Controlled Trials

Bashar M Al Zoubi

Poster Presenter: Bashar M Al Zoubi

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.